JPMorgan发展中市场股票主动型ETF JADE 深 沪
交易中 07-14 11:11:53 美东时间
76.3299
0.000
0.00%
华盛通- 最 高0.00
- 今 开76.3299
- 成交量 18股
- 最 低 0.00
- 昨 收 76.3299
- 总市值 3053.20万
- 52周最高 82.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 52.4837
- 委 比 -98.02%
- 总股本 40.00万
- 历史最高 82.75
- 量 比 0.05
- 振 幅 0.00%
- 历史最低 40.7433
- 每 手 1
- 风险率 8.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Jade Biosciences Prices Public Offering Of 10 Million Shares at $15 Per Share
BRIEF-Jade Biosciences Prices Public Offering Of 10 Million Shares at $15 Per Share June 3 (Reuters) - Jade Biosciences Inc JBIO.O : JADE BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK JADE BIOSCIENCES - PUBLIC OFFERING PRICED AT $15 PER SHARE JADE BIOSCIENCES - PRICES PUBLIC OFFER
06-04 11:03
Jade Biosciences plans public offering, pre-funded warrants
Jade Biosciences (JBIO) on Wednesday said it intends to offer shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants in an underwritten public offering. The com...
06-04 04:26
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analyst addresses ADA concerns and timeline expectations.
06-02 01:59
Jade Biosciences Doses First Patient In Phase 1 Clinical Study Of JADE201; Anticipates Interim First-In-Human Data Next Year
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has
05-27 04:06
业聚医疗（6929.HK）：全年业绩再创新高，核心经营利润增20.2%，全球化与创新双轮驱动彰显韧性
2025年，全球医疗器械行业仍在关税扰动与地缘政治变局中艰难前行。业聚医疗却逆势交出一份硬核成绩单：收入与销量连续五年创下历史新高，核心经营利润同比猛增20....
03-16 08:51
BRIEF-Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update
BRIEF-Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update March 6 (Reuters) - Jade Biosciences Inc JBIO.O : JADE BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE JADE BIOSCIENCES INC: $336 MIL
03-06 20:27
Jade Biosciences Q4 R&D expenses rise to USD 28.5 million (+61.9%)
Jade Biosciences Q4 R&D expenses rise to USD 28.5 million (+61.9%) Jade Biosciences (JBIO) reported a FY 2025 net loss of USD 127.4 million and a Q4 2025 net loss of USD 31.9 million. FY 2025 R&D expenses were USD 93.1 million and FY 2025 G&A expenses were USD 20.4 million, while Q4 2025 R&D expense
03-06 20:00
Jade Biosciences Provides Pipeline Update: JADE101 Phase 1 Ongoing, Phase 2 In IgA Nephropathy Mid-26; JADE201 First-In-Human RA Study 2Q26; JADE301 Nominated With Phase 1 Planned 1H27
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026;
01-05 20:14
BRIEF-Jade Biosciences Files For Offering Of 3.2 Million Shares Of Common Stock By Selling Stockholder- SEC Filing
Dec 22 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES FILES FOR OFFERING OF 3.2 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER- SEC FILING Source text: [ID:n0001193125-25-328848] Fur...
2025-12-23 06:54
RPT-ROI-Oil’s geopolitical premium vanished in 2025 - and may not return: Bousso
Repeats to additional subscribers without any changes. The opinions expressed here are those of the author, a columnist for Reuters. By Ron Bousso LONDON, Dec 22 (Reuters) - Global oil markets faced m...
2025-12-22 19:00
